Frequent coauthors
- TEGLEY Christopher M. 96
- JONES Todd K. 96
- EDWARDS James P. 88
- FENSOME ANDREW 88
- GRUBB Gary S. 88
- ZHI LIN 88
- WROBEL Jay E. 80
- ZHANG Puwen 72
- FLETCHER III HORACE 24
- MARSCHKE Keith B. 16
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single sub…